<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Mixed-salt oxybate (gamma hydroxybutyrate): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Mixed-salt oxybate (gamma hydroxybutyrate): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Mixed-salt oxybate (gamma hydroxybutyrate): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_pediatric" data-topicid="129187" href="/d/html/129187.html" rel="external">see "Mixed-salt oxybate (gamma hydroxybutyrate): Pediatric drug information"</a> and <a class="drug drug_patient" data-topicid="129227" href="/d/html/129227.html" rel="external">see "Mixed-salt oxybate (gamma hydroxybutyrate): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F54702312"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Central nervous system depression</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;margin-left:2em;">Oxybate salts (calcium, magnesium, potassium, and sodium) are CNS depressants. Clinically significant respiratory depression and obtundation may occur in patients treated with oxybate salts (calcium, magnesium, potassium, and sodium) at recommended doses. Many patients who received oxybate salts (calcium, magnesium, potassium, and sodium) during clinical trials in narcolepsy and idiopathic hypersomnia were receiving CNS stimulants.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Abuse and misuse</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;margin-left:2em;">The active moiety of oxybate salts (calcium, magnesium, potassium, and sodium) is oxybate or gamma-hydroxybutyrate (GHB). Abuse or misuse of illicit GHB, either alone or in combination with other CNS depressants, is associated with CNS adverse reactions, including seizure, respiratory depression, decreases in the level of consciousness, coma, and death.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Restricted access</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;margin-left:2em;">Because of the risks of CNS depression and abuse and misuse, oxybate salts (calcium, magnesium, potassium, and sodium) is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the XYWAV and XYREM REMS.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F54873693"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Xywav</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F58885195"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Xywav</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F54702314"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Central Nervous System Depressant</li></ul></div>
<div class="block doa drugH1Div" id="F54799654"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="90b52f8e-db4b-4a27-9045-a3be3c626ea6">Hypersomnia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypersomnia (idiopathic): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Once-nightly dosing: </i>Initial: Oral: </b> ≤3 g at bedtime after the patient is in bed. May increase nightly dose by ≤1.5 g at weekly intervals based on efficacy and tolerability; maximum dose: 6 g/night.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Twice-nightly dosing: </i>Initial: Oral:</b> ≤2.25 g at bedtime after the patient is in bed and ≤2.25 g taken 2.5 to 4 hours later (≤4.5 g/night). May increase nightly dose by ≤1.5 g (≤0.75 g at bedtime and ≤0.75 g 2.5 to 4 hours later) at weekly intervals based on efficacy and tolerability; maximum dose: 9 g/night. <b>Note:</b> Some patients may achieve better responses with unequal nightly doses at bedtime and 2.5 to 4 hours later.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f8711007-1017-4637-a97c-593e06f5423f">Narcolepsy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Narcolepsy: Oral:</b> Initial: 2.25 g at bedtime after the patient is in bed, and 2.25 g taken 2.5 to 4 hours later (4.5 g/night). May increase nightly dose by 1.5 g (0.75 g at bedtime and 0.75 g 2.5 to 4 hours later) at weekly intervals based on efficacy and tolerability; usual effective dosage range: 6 to 9 g/night. Maximum dose: 9 g/night.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<i>Missed second dose: </i>Skip dose and resume usual dosing schedule the next day. Do not administer 2 doses at the same time.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Conversion from sodium oxybate to oxybate salts (calcium, magnesium, potassium, and sodium): </i>On the first night of dosing with oxybate salts (calcium, magnesium, potassium, and sodium), initiate treatment at the same dose (gram for gram) and regimen as sodium oxybate.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:0em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F54799656"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); however, not renally eliminated.</p></div>
<div class="block doha drugH1Div" id="F54799657"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">Reduce initial dose by 50%.</p></div>
<div class="block doe drugH1Div" id="F54799655"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing; use with caution.</p></div>
<div class="block dop drugH1Div" id="F54707876"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="129187" href="/d/html/129187.html" rel="external">see "Mixed-salt oxybate (gamma hydroxybutyrate): Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f8711007-1017-4637-a97c-593e06f5423f">Narcolepsy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Narcolepsy (excessive daytime sleepiness/cataplexy): Note:</b> Nightly, 2 doses are administered; some patients may require unequal doses to achieve optimal response. Dosing is presented as grams of oxybate.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥7 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">&lt;20 kg: Oral: There are no specific dosage recommendations in the manufacturer's labeling due to insufficient data; however, a lower initial starting dose and lower maximum dosages are recommended.</p>
<p style="text-indent:-2em;margin-left:6em;">20 to &lt;30 kg: Oral: Initial: ≤1 g at bedtime after the patient is in bed, then 2.5 to 4 hours later, administer second dose of ≤1 g. After 1 week, titrate dose based on efficacy and tolerability at weekly intervals; increase dose in ≤0.5 g/dose (≤1 g/night) increments per week; maximum single dose: 3 g/dose; maximum daily dose: 6 g/night.</p>
<p style="text-indent:-2em;margin-left:6em;">30 to &lt;45 kg: Oral: Initial: ≤1.5 g at bedtime after the patient is in bed, then 2.5 to 4 hours later, administer second dose of ≤1.5 g. After 1 week, titrate dose based on efficacy and tolerability at weekly intervals; increase dose in ≤0.5 g/dose (≤1 g/night) increments per week; maximum single dose: 3.75 g/dose; maximum daily dose: 7.5 g/ night.</p>
<p style="text-indent:-2em;margin-left:6em;">≥45 kg: Oral: Initial: ≤2.25 g at bedtime after the patient is in bed, then 2.5 to 4 hours later, administer second dose of ≤2.25 g . After 1 week, titrate dose based on efficacy and tolerability at weekly intervals; increase dose in ≤0.75 g/dose (≤1.5 g/night) increments per week; maximum single dose: 4.5 g/dose; maximum daily dose: 9 g/night.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Converting from sodium oxybate (Xyrem) to oxybate salts (calcium, magnesium, potassium, and sodium oxybate) (Xywav):</b> Discontinue sodium oxybate (Xyrem) and initiate oxybate salts (calcium, magnesium, potassium, and sodium) (Xywav) at the same dose (gram per gram); titrate as needed based on efficacy and tolerability.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F54707890"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block dohp drugH1Div" id="F54707892"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Children ≥7 years and Adolescents: Reduce initial total nightly dose by 50% and administer in 2 divided doses.</p></div>
<div class="block arsc drugH1Div" id="F55550070"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Behavioral and psychiatric effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Use of oxybate salts was associated with neuropsychiatric effects in adult and pediatric patients during clinical trials, including <b>agitation,</b>
<b>anxiety</b>, <b>confusion</b>, <b>irritability,</b>
<b>panic attack,</b>
<b>tension,</b> and <b>visual hallucinations</b>; aggression, paranoia, and psychosis have also been reported with sodium oxybate (which has the same active moiety as oxybate salts).</p>
<p style="text-indent:-2em;margin-left:4em;">Treatment discontinuation has been reported in patients who experienced neuropsychiatric effects.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">CNS and respiratory depression</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Clinically significant <b>central nervous system</b> (CNS) <b>depression, respiratory depression,</b> and <b>obtundation</b> may occur in adult and pediatric patients, even at recommended doses. Increased apnea (including sleep-related apnea) and clinically relevant reduced oxygenation may also occur. CNS and respiratory depression are reversible following dosage modification, interruption of therapy, and/or discontinuation.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related (Teter 2001); related to the pharmacologic action (ie, GABA<sub>B</sub> receptor activity)</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Rapid</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant use with other CNS depressants (eg, opioids, benzodiazepines, sedating antidepressants/antipsychotics/antiseizure medications, general anesthetics, muscle relaxants, illicit CNS depressants); associated with an increased risk of respiratory depression, hypotension, profound sedation, syncope, and death. <b>Note:</b> Use of oxybate salts is contraindicated with alcohol and sedative hypnotics.</p>
<p style="text-indent:-2em;margin-left:6em;">• Impaired respiratory drive:</p>
<p style="text-indent:-2em;margin-left:8em;">- Preexisting compromised respiratory function</p>
<p style="text-indent:-2em;margin-left:6em;">• Sleep-related breathing disorders:</p>
<p style="text-indent:-2em;margin-left:8em;">- Obesity</p>
<p style="text-indent:-2em;margin-left:8em;">- Male patients</p>
<p style="text-indent:-2em;margin-left:8em;">- Female patients who are postmenopausal and not on hormone-replacement therapy</p>
<p style="text-indent:-2em;margin-left:8em;">- Patients with narcolepsy</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Parasomnias</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Parasomnias</b>, including <b>abnormal dreams, night terrors, sleep paralysis, sleep talking,</b> and <b>somnambulism</b>, have been reported in both adult and pediatric patients during clinical trials. Parasomnias have led to treatment discontinuation.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Suicidal thinking and behavior</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Treatment with oxybate salts was associated with an increased incidence of <b>depression </b>(including <b>depressed mood</b>), <b>suicidal ideation,</b> and <b>suicidal tendencies</b> in both adult and pediatric patients during clinical trials. Treatment discontinuation secondary to depression was also reported.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:4em;">• Prior history of depression and/or suicide attempt</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F54730307"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (20%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Diaphoresis (including night sweats: 6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Decreased appetite (8%), diarrhea (6%), vomiting (5%), xerostomia (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary incontinence (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Anxiety (including agitation, panic attack, and tension: 5%), confusion (1%), depressed mood (4%), depression (3%), dizziness (10%), drowsiness (2%), fatigue (including asthenia: 4%), irritability (3%), parasomnias (including abnormal dreams, night terrors, sleep paralysis, sleep talking, and somnambulism with a potential for injury: 6%), paresthesia (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Muscle spasm (2%), tremor (3%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%: Nervous system: Visual hallucination</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Central nervous system depression, obtundation, suicidal ideation, suicidal tendencies</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Respiratory depression</p></div>
<div class="block coi drugH1Div" id="F54702317"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Concomitant use with sedative hypnotics or alcohol; succinic semialdehyde dehydrogenase deficiency.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Hypersensitivity to oxybate salts (calcium, magnesium, potassium, and sodium) or any component of the formulation.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block war drugH1Div" id="F54799638"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Disease-related concerns:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic insufficiency: Use with caution in patients with preexisting liver impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Other warnings/precautions:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Tolerance/withdrawal: Tolerance to oxybate salts (calcium, magnesium, potassium, and sodium), or withdrawal following its discontinuation, has not been clearly defined in controlled clinical trials, but has been reported at larger doses used for illicit purposes.</p></div>
<div class="block dosfc drugH1Div" id="F54703941"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:0em;display:inline">Each mL contains 0.5 g of oxybate salts present as 0.234 g calcium oxybate, 0.096 g magnesium oxybate, 0.13 g potassium oxybate, and 0.04 g sodium oxybate.</p></div>
<div class="block foc drugH1Div" id="F54873694"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Xywav: 500 mg/mL (180 mL) [barley free, gluten free, rye free, wheat free]</p></div>
<div class="block geq drugH1Div" id="F54873692"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F54962694"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Xywav Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg/mL (per mL): $41.87</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F58885196"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Xywav: 500 mg/mL (180 mL)</p></div>
<div class="block csi drugH1Div" id="F54799635"><span class="drugH1">Controlled Substance</span>
<p style="text-indent:0em;display:inline">C-I (illicit use); C-III (medical use)</p></div>
<div class="block accres drugH1Div" id="F59011596"><span class="drugH1">Prescribing and Access Restrictions</span>
<p style="text-indent:0em;display:inline">
<i>Canada:</i> Available through a controlled distribution program. Registration with the program is required for participating prescribers and pharmacists. Patients must also be registered with the program and meet all necessary requirements to receive oxybate salts. For further information, call 1-866-599-7365 or write to <a class="__cf_email__" data-cfemail="421a1112022b2c2c2d2f23306f313630233627252b27316c212d2f" href="/cdn-cgi/l/email-protection">[email protected]</a>.</p></div>
<div class="block adm drugH1Div" id="F54799658"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> Administer on an empty stomach, ≥2 hours after eating. Administer dose at bedtime. For patients taking a second nightly dose, administer second dose 2.5 to 4 hours after the first dose; an alarm clock may need to be set for the second dose. Prepare both doses prior to bedtime. Prior to ingestion, dilute each dose with approximately ¼ cup water in provided empty pharmacy containers. Administer both doses while patient is in bed; patient should lie down immediately after dose and remain in bed.</p></div>
<div class="block admp drugH1Div" id="F54707897"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer on an empty stomach (at least 2 hours after eating); administration at similar times each night is preferred. Each nightly dose should be administered while patient is sitting up in bed, then patient should immediately lie down and remain in bed; sleep generally occurs within 5 to 15 minutes (generally abruptly without patient feeling drowsy). Both doses should be prepared prior to bedtime. The first dose is administered at bedtime and the second dose is administered 2.5 to 4 hours later; an alarm clock may need to be set for the second dose. For patients who sleep &gt;8 hours per night the first dose may be administered at bedtime or after an initial period of sleep. After use, rinse containers with water.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Missed dose:</i> If the second dose is missed, skip that dose and resume therapy the next night; do not administer both doses at the same time. Diluted doses that are not used should be properly and promptly disposed.</p></div>
<div class="block meg drugH1Div" id="F56092013"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F212690s011lbl.pdf%23page%3D29&amp;token=xjNAQuTFb9WH%2Fkrax6KLXVLExMl4TG9qssewriEHQBsbznKt8slGyUZtuEi6g3xJJ5XAnp90A16dyIdlYbTo1SuJgZ3tB2AEaSxDnU1BYPGzAAETN0ytYM9b8pEVrbIx&amp;TOPIC_ID=129186" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212690s011lbl.pdf#page=29</a>, must be dispensed with this medication.</p></div>
<div class="block use drugH1Div" id="F54702316"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypersomnia (idiopathic):</b> Treatment of idiopathic hypersomnia in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Narcolepsy:</b> Treatment of cataplexy or excessive daytime sleepiness in patients ≥7 years of age with narcolepsy.</p></div>
<div class="block mst drugH1Div" id="F54799633"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Oxybate salts (calcium, magnesium, potassium, and sodium) may be confused with sodium oxybate.</p>
<p style="text-indent:-2em;margin-left:4em;">Xywav may be confused with Xyrem.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F54750588"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F54750585"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): May enhance the CNS depressant effect of Oxybate Salt Products. Alcohol (Ethyl) may increase the serum concentration of Oxybate Salt Products. Specifically, alcohol may increase concentrations of the sodium oxybate extended release suspension.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alizapride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Azelastine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benzodiazepines: May enhance the CNS depressant effect of Oxybate Salt Products.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin.  Management: Use caution if coadministering blonanserin and CNS depressants; dose reduction of the other CNS depressant may be required. Strong CNS depressants should not be coadministered with blonanserin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: CNS Depressants may enhance the CNS depressant effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CNS Depressants: May enhance the CNS depressant effect of Oxybate Salt Products. Management: Consider alternatives to this combination when possible. If combined, dose reduction or discontinuation of one or more CNS depressants (including the oxybate salt product) should be considered. Interrupt oxybate salt treatment during short-term opioid use<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DexmedeTOMIDine: CNS Depressants may enhance the CNS depressant effect of DexmedeTOMIDine.  Management: Monitor for increased CNS depression during coadministration of dexmedetomidine and CNS depressants, and consider dose reductions of either agent to avoid excessive CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Difelikefalin: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroPERidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (eg, opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: CNS Depressants may enhance the CNS depressant effect of Flunarizine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants. Management: Consider a decrease in the CNS depressant dose, as appropriate, when used together with hydroxyzine. Increase monitoring of signs/symptoms of CNS depression in any patient receiving hydroxyzine together with another CNS depressant.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypnotics (Nonbenzodiazepine): May enhance the CNS depressant effect of Oxybate Salt Products.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kava Kava: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lisuride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce the usual dose of CNS depressants by 50% if starting methotrimeprazine until the dose of methotrimeprazine is stable. Monitor patient closely for evidence of CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Minocycline (Systemic): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olopatadine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: CNS Depressants may enhance the CNS depressant effect of Opioid Agonists.  Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Procarbazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rilmenidine: Oxybate Salt Products may enhance the CNS depressant effect of Rilmenidine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased.  Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valerian: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valproate Products: May increase the serum concentration of Oxybate Salts (Calcium, Magnesium, Potassium, and Sodium). Management: Decrease the dose of oxybate salts by at least 20% when initiating therapy with valproate products. When initiating oxybate salts in patients taking valproate products, use a lower starting dose of oxybate salts.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuranolone: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to the use of zuranolone with other CNS depressants or alcohol. If combined, consider a zuranolone dose reduction and monitor patients closely for increased CNS depressant effects.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block foi drugH1Div" id="F54799641"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Administration of oxybate salts (calcium, magnesium, potassium, and sodium) immediately following a high-fat meal decreases gamma-hydroxybutyrate C<sub>max </sub>by 33% and AUC by 16%. Management: Administer first nightly dose at least 2 hours after eating.</p></div>
<div class="block pri drugH1Div" id="F54799636"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">The active moiety of oxybate salts, gamma-hydroxybutyrate, crosses the placenta. The injection formulation of sodium oxybate, when used as an anesthetic during labor and delivery, was shown to cause a slight decrease in Apgar scores due to sleepiness in the neonate.</p></div>
<div class="block brc drugH1Div" id="F54799637"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">The active moiety of oxybate salts, gamma-hydroxybutyrate, is present in breast milk following oral administration of sodium oxybate.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F54799660"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Emergent or worsening depression, suicidal ideation, emergence or increase in the occurrence of behavioral or psychiatric events; impaired motor/cognitive function; signs of drug abuse, misuse, substance use disorder, or diversion.</p></div>
<div class="block pha drugH1Div" id="F54799643"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">The active moiety of oxybate salts (calcium, magnesium, potassium, and sodium) is oxybate or gamma-hydroxybutyrate (GHB). The therapeutic effects of GHB, a metabolite of GABA, are hypothesized to be mediated by GABA<sub>B</sub> receptor activity at noradrenergic, dopaminergic, and thalamocortical neurons.</p></div>
<div class="block phk drugH1Div" id="F54799644"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset: Rapid (≤5 to 15 minutes).</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 190 to 384 mL/kg.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: &lt;1%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Primarily via the Krebs cycle to form water and carbon dioxide; secondarily via beta oxidation; no active metabolites.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: ~0.66 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: ~1.3 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Primarily via biotransformation to carbon dioxide and expiration; Urine: &lt;5% as unchanged drug.</p></div>
<div class="block phksp drugH1Div" id="F54799652"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">Hepatic function: AUC is doubled, elimination half-life is longer, and oral clearance is reduced in cirrhotic patients (Child-Pugh class A and C).</p></div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-Xywav.1">
<a name="Xywav.1"></a>Xywav (calcium, magnesium, potassium, and sodium oxybate) [prescribing information]. Palo Alto, CA: Jazz Pharmaceuticals Inc; April 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Xywav.2">
<a name="Xywav.2"></a>Xywav (calcium, magnesium, potassium, and sodium oxybate) [product monograph]. Oakville, Ontario, Canada: Innomar Strategies Inc; May 2023.</div>
</li></ol></div><div id="topicVersionRevision">Topic 129186 Version 88.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
